Effects of TOTUM-448 on liver fat and heart health
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a supplement called TOTUM-448 to see if it can reduce liver fat and improve heart health in people with a fatty liver condition (MASLD). If you have excess liver fat and are overweight, this study could help find new ways to manage your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a certain amount of fat in your liver (measured by a special scan).
- Your body mass index (BMI) is between 25 and 40, and your waist size is within a specific range.
- Your weight has been stable (within 5%) for the last 3 months.
- You do not drink more than 10 drinks per week (for women) or 15 drinks per week (for men).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether changing when and how people eat can improve fatty liver disease caused by metabolic problems. It uses MRI to measure liver fat and compares outcomes while participants follow a structured eating schedule.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
Hear when a new Non-Alcoholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.